ymruzavtra - FACEIT level 10, 2,545 ELO

Russia
On FACEIT since 2021 191 matches tracked 53 matches in 30 days
ELO ▼ 42
2,545
30-day peak: 2,617
Rank EU
#45,118
Russia #11,675 in Russia
Last updated:

ymruzavtra at a glance

Level 10 2,545 ELO best map Mirage (60%)
2,500-2,749 ELO

Last 20 matches compared with 2,991 players in this group: K/R and ADR below average, win rate above average.

RatingCalculated with the HLTV Rating 1.0 formula from kills, deaths and multi-kills per round. 1.00 is an average match.
better than 10%
0.89
SpreadHow much the rating swings from match to match. The smaller, the more consistent. ±0.44 ConsistencyShare of matches with a rating of 0.90 or higher. 50%
K/R
0.63
better than 9% of players
2,500-2,749 ELO avg: 0.74
Last 12 months
ADR
70.8
better than 9% of players
2,500-2,749 ELO avg: 81.1
Last 12 months
Win rate
55%
better than 59% of players
2,500-2,749 ELO avg: 50%
Last 12 months

Facts

96 ELO Next goal ELO to the peak (2,641)
3 Comebacks last 90 days
2 W · 4 L Overtime in overtime
Dust 2 Favorite map 52 of 190 matches
Mirage 60% Map pool tip weakest: Nuke 39%
2 knife kills Rare kills last 90 days
On Fridays Playing times most active
FormMapsTiming

96 ELO away from the recorded peak (2,641). 3 wins after trailing at halftime (last 90 days). 6 matches in overtime, 2 of them won (last 90 days). Most played: Dust 2 (52 of 190 matches). Strongest map: Mirage (60% win rate, 48 matches). Weakest: Nuke (39%, 23 matches). 2 knife kills (last 90 days). Plays most on Fridays (based on 190 matches).

About ymruzavtra

ymruzavtra plays CS2 on FACEIT level 10 with 2,545 ELO. The stats cover 190 matches. The strongest map is Mirage with a 60% win rate in 48 matches. Most played: Dust 2 with 52 matches and a 42% win rate. Biggest strength: Deaths per round at just 68% (lower is better), better than 84% of level 10 · 2,500-2,749 ELO players. ymruzavtra won 3 matches after trailing at halftime (last 90 days). Last 20 matches: 11 wins, 9 losses, +84 ELO. Previously known as Musor_Drop62 and LXVII.